CTAD 2023: Subcutaneous Leqembi Bests I.V., Could Open Access

At-Home Option An Important Growth Driver for Eisai/Biogen

 
• By Mandy Jackson
  
Alzheimer's disease, Amyloid plaques aggregates, 3d illustration
Amyloid plaque clearance was 14% greater with subcutaneous Leqembi • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D